Search

Your search keyword '"Lingvay I"' showing total 306 results

Search Constraints

Start Over You searched for: Author "Lingvay I" Remove constraint Author: "Lingvay I"
306 results on '"Lingvay I"'

Search Results

1. GASSING OF THE ELECTRICAL INSULATING FLUIDS - A DETERMINANT FACTOR OF THE TRANSFORMERS SAFETY IN OPERATION

2. STUDY OF SOME INSULATING OILS AGING BY THERMAL CYCLING

3. DURABILITY OF ANTICORROSIVE PROTECTION COATINGS FOR ELECTRO-ENERGETIC EQUIPMENT

4. THERMOCHEMICAL STABILITY OF INSULATING OILS

5. CONTRIBUTIONS TO EVALUATION OF THE BIODEGRADABILITY BY ASPERGILLUS NIGER AND OTHER FUNGI’S OF SOME INSULATING OILS

9. Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once‐weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1‐5, 7‐10 and SUSTAIN China

11. Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once‐weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1‐5, 7‐10 and SUSTAIN China.

13. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin

16. Sémaglutide 2,4 mg administré de manière hebdomadaire améliore le métabolisme du glucose et le prédiabète chez des adultes en situation de surpoids ou d’obésité dans l’étude clinique STEP 1

21. Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial

25. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes

26. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial

27. Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE

28. Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE

29. Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE

30. Serum urate lowering with allopurinol and kidney function in type 1 diabetes

31. Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin

32. Effects of canagliflozin on cardiovascular death and hospitalization for heart failure by baseline estimated glomerular filtration rate: integrated analyses from the CANVAS Program and CREDENCE

34. Liraglutide and Renal Outcomes in Type 2 Diabetes

35. Hyposialylated IgG activates endothelial IgG receptor Fc gamma RIIB to promote obesity-induced insulin resistance

37. Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine regardless of the hypoglycaemia definition used

45. Des taux plus faibles d’hypoglycémies avec insuline degludec / liraglutide (IDegLira) versus insuline GlargineU100 (IGlar U100) chez les diabétiques de type 2 quels que soient l’horaire d’administration ou le mode de définition des hypoglycémies

46. Insulin degludec/Liraglutid (IDegLira) verbesserte bei Patienten mit Typ 2 Diabetes (T2D) mit unzureichender Blutzuckereinstellung unter Insulin glargin (IGlar) plus Metformin (Met) die Leistungsfähigkeit und das Wohlbefinden (Patient Reported Outcomes): DUAL-V-Studie

Catalog

Books, media, physical & digital resources